Skip to main content
SpringerLink
Log in

Genetic polymorphisms in SCN2A are not associated with epilepsy risk and AEDs response: evidence from a meta-analysis

  • Review Article
  • Published:
Neurological Sciences Aims and scope Submit manuscript

Abstract

Background

Previous studies have investigated the association between rs2304016 and rs17183814 polymorphisms in sodium voltage-gated channel alpha subunit 2 (SCN2A) and epilepsy risk and responsiveness to antiepileptic drugs (AEDs) but with conflicting results. Our aim was to reevaluate the relationship by performing a systematic review and meta-analysis.

Methods

By searching PubMed, Medline, and CNKI, 14 studies were selected. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were computed to measure the association between rs17183814 and rs2304016 polymorphisms and the risk of epilepsy and AEDs response using the fixed-effects model or the random-effects model.

Results

No significant association between the rs17183814 in SCN2A and the risk of epilepsy was observed (heterozygous comparison: OR = 0.78, 95% CI: 0.61–1.00; homozygous comparison: OR = 1.34, 95% CI: 0.63–2.86; dominant model: OR = 0.82, 95% CI: 0.64–1.04; recessive model: OR = 1.44, 95% CI: 0.68–3.05; allele comparison: OR = 0.88, 95%CI: 0.71–1.10). Moreover, neither the rs17183814 nor the rs2304016 was associated with AEDs response.

Conclusion

This meta-analysis suggests that the rs17183814 and rs2304016 polymorphisms in SCN2A are not associated with the risk of epilepsy and response to AEDs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Fischer et al (2014) ILAE official report: a practical clinical definition of epilepsy. Epilepsia 55(4):475–482

    Article  Google Scholar 

  2. Lakhan R et al (2009) Differential role of sodium channels SCN1A and SCN2A gene polymorphisms with epilepsy and multiple drug resistance in the north Indian population. Br J Clin Pharmacol 68(2):214–220

    Article  CAS  Google Scholar 

  3. Catterall WA, Goldin AL, Waxman SG (2005) International Union of Pharmacology. XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels. Pharmacol Rev 57(4):397–409

    Article  CAS  Google Scholar 

  4. Sanders SJ, Campbell AJ et al (2018) Progress in understanding and treating SCN2A-mediated disorders. Trends Neurosci 41(7):442–456

    Article  CAS  Google Scholar 

  5. Kwan P et al (2008) Multidrug resistance in epilepsy and polymorphisms in the voltage-gated sodium channel genes SCN1A, SCN2A, and SCN3A: correlation among phenotype, genotype, and mRNA expression. Pharmacogenet Genomics 18(11):989–998

    Article  CAS  Google Scholar 

  6. Lv WP, Han RF, Shu ZR (2014) Associations between the C3435T polymorphism of the ABCB1 gene and drug resistance in epilepsy: a meta-analysis. Int J Clin Exp Med 7(11):3924–3932

    PubMed  PubMed Central  Google Scholar 

  7. Howell KB, McMahon JM, Carvill GL, Tambunan D, Mackay MT, Rodriguez Casero V et al (2015) SCN2A encephalopathy: a major cause of epilepsy of infancy with migrating focal seizures. Neurology 85(11):958–966

    Article  CAS  Google Scholar 

  8. Carroll LS, Woolf R, Ibrahim Y, Williams HJ, Dwyer S, Walters J et al (2016) Mutation screening of SCN2A in schizophrenia and identification of a novel loss-of-function mutation. Psychiatr Genet 26(2):60–65

    Article  CAS  Google Scholar 

  9. Ben-Shalom R, Keeshen CM, Berrios KN, An JY, Sanders SJ, Bender KJ (2017) Opposing effects on NaV1.2 function underlie differences between SCN2A variants observed in individuals with autism spectrum disorder or infantile seizures. Biol Psychiatry 82(3):224–232

    Article  CAS  Google Scholar 

  10. AlSaif S, Umair M, Alfadhel M (2019) Biallelic SCN2A gene mutation causing early infantile epileptic encephalopathy: case report and review. J Cent Nerv Syst Dis 11:1179573519849938

  11. Liao Y, Anttonen A-K, Liukkonen E, Gaily E, Maljevic S, Schubert S et al (2010) SCN2A mutation associated with neonatal epilepsy, late-onset episodic ataxia, myoclonus, and pain. Neurology 75(16):1454–1458

    Article  CAS  Google Scholar 

  12. Monlong J et al (2018) Global characterization of copy number variants in epilepsy patients from whole genome sequencing. PLoS Genet 14(4):e1007285

    Article  Google Scholar 

  13. Orlandi A et al (2018) Clinical reappraisal of the influence of drug-transporter polymorphisms in epilepsy. Expert Opin Drug Metab Toxicol 14(5):505–512

    Article  CAS  Google Scholar 

  14. Schwarz N, Bast T, Gaily E, Golla G, Gorman KM, Griffiths LR et al (2019) Clinical and genetic spectrum of SCN2A-associated episodic ataxia Eur. J Paediatr Neurol 23(3):438–447

    Article  CAS  Google Scholar 

  15. (2004) A nonsense mutation of the sodium channel gene SCN2A in A patient with intractable epilepsy and mental decline. J Neurosci 24(11):2690–2698

  16. Liao Y, Deprez L, Maljevic S, Pitsch J, Claes L, Hristova D et al (2010) Molecular correlates of age-dependent seizures in an inherited neonatal-infantile epilepsy. Brain 133(5):1403–1414

    Article  Google Scholar 

  17. Haerian BS, Baum L et al (2013) SCN1A, SCN2A and SCN3A gene polymorphisms and responsiveness to antiepileptic drugs: a multicenter cohort study and meta-analysis. Pharmacogenomics. 14(10):1153–1166

    Article  CAS  Google Scholar 

  18. Senior K (2005) Gene variants affect response to antiepileptic drugs. Lancet Neurol 4(5):276–277

    Article  Google Scholar 

  19. Mantegazza M et al (2010) Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders. Lancet Neurol 9(4):413–424

    Article  CAS  Google Scholar 

  20. Zuliani V, Fantini M, Rivara M (2012) Sodium channel blockers as therapeutic target for treating epilepsy: recent updates. Curr Top Med Chem 12(9):962–970

    Article  CAS  Google Scholar 

  21. Hedrich UBS, Lauxmann S, Lerche H (2019) SCN2A channelopathies: mechanisms and models. Epilepsia. 60 Suppl 3:S68–S76

    PubMed  Google Scholar 

  22. Alekov A et al (2000) A sodium channel mutation causing epilepsy in man exhibits subtle defects in fast inactivation and activation in vitro. J Physiol 529 Pt 3(Pt 3):533–539

    Article  CAS  Google Scholar 

  23. Vilin YY, Ruben PC (2001) Slow inactivation in voltage-gated sodium channels: molecular substrates and contributions to channelopathies. Cell Biochem Biophys 35(2):171–190

    Article  CAS  Google Scholar 

  24. Xu X, Guo F, Lv X, Feng R et al (2013) Abnormal changes in voltage-gated sodium channels Na(V)1.1, Na(V)1.2, Na(V)1.3, Na(V)1.6 and in calmodulin/calmodulin-dependent protein kinase II, within the brains of spontaneously epileptic rats and tremor rats. Brain Res Bull 96:1–9

    Article  CAS  Google Scholar 

  25. Sisodiya SM (2005) Genetics of drug resistance. Epilepsia 46 Suppl 10:33–38

    Article  Google Scholar 

  26. Janssen RJ et al (2000) A branch site mutation leading to aberrant splicing of the human tyrosine hydroxylase gene in a child with a severe extrapyramidal movement disorder. Ann Hum Genet 64(Pt 5):375–382

    Article  CAS  Google Scholar 

  27. Shi L et al (2019) SCN1A and SCN2A polymorphisms are associated with response to valproic acid in Chinese epilepsy patients. Eur J Clin Pharmacol 75(5):655–663

    Article  CAS  Google Scholar 

  28. Haerian BS et al (2012) SCN1A IVS5N+5 polymorphism and response to sodium valproate: a multicenter study. Pharmacogenomics 13(13):1477–1485

    Article  CAS  Google Scholar 

  29. Pejanovic-Skobic N et al (2019) Lack of association of SCN2A rs17183814 polymorphism with the efficacy of lamotrigine monotherapy in patients with focal epilepsy from Herzegovina area, Bosnia and Herzegovina. Epilepsy Res 158:106221

    Article  CAS  Google Scholar 

  30. Ma CL et al (2015) SCN1A, ABCC2 and UGT2B7 gene polymorphisms in association with individualized oxcarbazepine therapy. Pharmacogenomics 16(4):347–360

    Article  CAS  Google Scholar 

Download references

Funding

This work was supported by the grants from West China Hospital, Sichuan University (No. TJZ202006 and 20HXJS007), the Key Project for Science and Technology Department of Sichuan Province (No. 2018SZ0216), and Sichuan University (No. 2017scu11038).

Author information

Author notes

  1. Ruiqing Yang and Ruiyi Qian contributed equally to this work.

Authors and Affiliations

  1. West China School of Medicine, Sichuan University, Chengdu, 610041, Sichuan, China

    Ruiqing Yang, Ruiyi Qian, Kerun Chen & Wei Yi

  2. Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China

    Xiutian Sima

Authors
  1. Ruiqing Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ruiyi Qian
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kerun Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wei Yi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xiutian Sima
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

SMXT designed and revised the manuscript. YR and QR collected the data and drafted the manuscript. CK and YW helped to check the data and performed statistical analysis.

Corresponding author

Correspondence to Xiutian Sima.

Ethics declarations

Conflict of interest

None.

Ethical approval and Informed consent

None.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

ESM 1

(PDF 55 kb).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yang, R., Qian, R., Chen, K. et al. Genetic polymorphisms in SCN2A are not associated with epilepsy risk and AEDs response: evidence from a meta-analysis. Neurol Sci 42, 2705–2711 (2021). https://doi.org/10.1007/s10072-021-05242-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10072-021-05242-x

Keywords

Search

Navigation